Routes of Administration
Routes of administration determine how drugs, fluids, vaccines and biologics reach target tissues—IV/IO, IM/SC, oral, intranasal, inhalation, transdermal and implantable systems. Route choice governs onset, bioavailability, stability, infection risk and logistical footprint; optimizing administration enables faster hemorrhage resuscitation, effective prophylaxis, and sustained therapy in prolonged-field care.
Technical Challenges
Delayed vascular access in polytrauma, crush and hypovolemic shock
Medication stability and cold-chain limitations in austere environments
Variable bioavailability and unpredictable absorption (oral, transdermal, intranasal)
Infection risk and biofilm formation at indwelling delivery sites
Limited patient-compliant or minimally trained administration options under stress
Emerging Opportunities
Rapid, reliable non-IV alternatives that match IV onset and bioavailability
Compact, ruggedized delivery systems with extended shelf life without cold chain
Field-suitable formulations for mass prophylaxis and inhaled/IN vaccines
Low-skill devices for prolonged-field care and delayed evacuation scenarios
Current and Emerging Technologies in Routes of Administration
Intravenous (IV) and Intraosseous (IO) access
Gold-standard for resuscitation and rapid drug delivery. IO provides emergent access when peripheral IV fails; innovations focus on faster placement, antimicrobial coatings, and miniaturized fluid warmers.
Intramuscular (IM) and Subcutaneous (SC) injections
Widely used for vaccines and depot therapeutics. Research targets auto-injectors, microarray/needle-free devices, and long-acting depot formulations to extend protection with single-dose administration.
Intranasal and inhalation delivery
Mucosal routes enable needle-free, rapid systemic or local action (e.g., naloxone, influenza vaccines). Advances include absorption enhancers, dry-powder inhalers, and aerosolized biologics for mass administration.
Oral and enteral formulations
Preferred for logistics and compliance but limited by GI absorption and first-pass metabolism. Innovations target prodrugs, mucoadhesive systems, and enteral feeds compatible with field nutrition and analgesia.
Transdermal and topical systems
Patches, microneedle arrays and topical formulations offer sustained release and simplified administration. Emerging work improves permeability, temperature stability, and dosing precision for vaccines and analgesics.
Implantable pumps and long-acting depots
Reservoirs, implanted ports and osmotic pumps support chronic or prolonged-field therapies. Focus areas include refillable, antimicrobial, and remotely programmable devices for extended physiologic support.
Combination technologies and formulation science
Nanocarriers, stabilizing excipients, adjuvants and smart-release matrices are being integrated to improve stability, target specificity and dose sparing—critical where logistics constrain supply.
Importance to Military Medicine
Life-saving timeliness
Faster onset routes and reliable alternatives to IV/IO reduce morbidity and mortality in hemorrhage, shock and airway emergencies.
Prolonged and distributed care
Field-stable, easy-to-use delivery systems enable hours-to-days of care when evacuation is delayed or resources are limited.
Operational logistics and readiness
Reduced cold-chain needs, compact devices and simplified administration lower logistic burden and increase force readiness.
Mass prophylaxis and force health protection
Needle-free and rapid-delivery options facilitate rapid immunization and chemoprophylaxis during outbreaks or biothreat events.
Alignment with the MTEC Mission
Directly advances MTEC’s DoD-focused mission by accelerating development of field-relevant delivery technologies that translate rapidly to operational use.
Supports cross-disciplinary projects spanning trauma care, infectious disease countermeasures, and prolonged care—areas within MTEC’s portfolio.
Emphasizes rapid transition to real-world use: ruggedized devices, stability-enhanced formulations and low-skill deployment tools that meet DoD timelines.
Enables dual-use impact—civilian emergency medicine and public health benefit from military-driven advances, consistent with MTEC’s translational goals.
Dual-Use (Military + Civilian) Applications
Emergency and prehospital care: needle-free naloxone, inhaled analgesics and rapid IM/auto-injectors for first responders and clinicians.
Public health and mass vaccination: stable, easy-to-administer formulations (dry-powder, microneedles) for rapid immunization without cold chain.
Chronic disease management: implantable or long-acting systems developed for austere care can improve adherence in civilian remote and underserved settings.
Disaster response and biodefense: compact, user-friendly delivery platforms expedite mass prophylaxis and therapeutics during outbreaks or exposures.
Explore MTEC Members with Routes of Administration Capabilities
MTEC members combine clinical trauma expertise, formulation science, device engineering and field testing to de-risk route-of-administration solutions. Consortium strengths include access to DoD clinical testbeds, rapid prototyping, regulatory strategy support and partnerships that accelerate translation from bench to battlefield.
Explore member profiles to discover innovators in IO/IV devices, microneedles, inhaled biologics, thermal-stable formulations and deployable administration systems—partners poised to advance military and civilian care.
96 Members with Routes of Administration capabilities.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.
Maverick Labs is a U.S.-based biotechnology and materials science company specializing in advanced protein design, synthetic biology, and microbial engineering. The company operates through three tightly integrated subsidiaries—Maverick Metals, Maverick Energy, and the Maverick Bio-Gene Therapy Translational Unit—each of which applies a shared technological foundation to tackle critical challenges across national defense, energy independence, and strategic material access. Together, they develop scalable, field-ready solutions that reinforce the United States’ industrial resilience and military readiness through biotechnology-driven innovation.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
Action Medical Technologies is a pharmaceutical and medical device company focused on developing innovative solutions that integrate medications with advanced devices and injector systems to improve patient outcomes, particularly in austere prehospital environments.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Memsel is a biotechnology research and development company dedicated to enhancing health and combatting infections through advanced phage therapies and targeted delivery systems. The company aims to transform healthcare solutions across human, animal, and plant domains, addressing critical health challenges and antibiotic resistance.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
Evimero is an interdisciplinary company focused on understanding the interactions between microorganisms and human health, agriculture, and the environment, utilizing Systems Biology and AI/ML. Evimero applies molecular principles to infectious disease and microbiome science to improve health outcomes and environmental sustainability through targeted interventions in dysbiotic microbiomes and in people with infectious disorders. Evimero has an infectious disease product pipeline including both prophylactic and diagnostic assets against common causes of Travelers' Diarrhea, including a unique approach to preventing infection with human Norovirus, enterotoxigenic E. coli (ETEC) and others. Evimero's pipeline of drugs targeting human and animal microbiomes includes early-stage assets aimed at generalized microbiome-driven inflammation and gut leak, and specific disease-targeted disorders including Parkinson Disease and Inflammatory Bowel Diseases. Evimero's platform also makes possible a suite of point-of-care diagnostics that can be used for patient cohorting (infectious diseases), risk stratification, and ultimately informing therapeutic decision-making. The nature of Evimero's platform assures a steady stream of novel assets targeting both infectious diseases and chronic disorders with roots in microbiome dysfunction.
VerimedRx is a medical device startup focused on transforming medication preparation and delivery through automated compounding with IV workflow software. The company aims to enhance the safety and efficiency of medication preparation in pharmacies by developing a small, easy-to-implement automated compounding device. This innovation addresses the challenges of manual IV compounding, which can lead to inaccuracies and scalability issues as patient infusions increase and regulatory demands grow. (Think "Keurig Machine for the Infusion Pharmacy")
Vivosang Inc is an investigational stage biotechnology company focused on developing pegylated human hemoglobin products to enhance oxygen delivery in medical applications, particularly in traumatic hemorrhagic injuries. Their lead product, VS-101, aims to provide targeted oxygen delivery to tissues in need, addressing significant medical needs in emergency and surgical settings.
Purgo Scientific is a medical device company dedicated to developing effective solutions for the biofilm infections crisis in orthopedic surgery. Their mission is to provide a locally targeted sustained delivery device that ensures the right therapy is delivered to the right place for the right duration, ultimately improving patient outcomes and reducing the impact of surgical site infections.
Pneuma Systems Corporation specializes in designing and licensing closed-loop fluid control systems that precisely manage small fluid volumes without the complexity of traditional pumping mechanisms. The company leverages over 30 inventions and three novel subsystems to revolutionize fluid flow, workflow, information flow, and cash flow, aiming to transform the standard of care in infusion therapy. Pneuma is a small team of experienced medical device professionals working on a new technology platform for precise fluid delivery, with an emphasis on infusion therapy. Armed with a strong IP portfolio, Pneuma’s infusion controller is designed to support all venues of infusion therapy including acute care, standalone infusion centers, and home care. The design offers significant advances in fluid flow, information flow, and work flow. The design has been accepted into an accelerated review program by the U.S. Food and Drug Administration (FDA), known as STeP.
Solventum is a healthcare company dedicated to enabling better, smarter, and safer healthcare solutions. With a legacy of innovation, Solventum focuses on improving patient outcomes through advanced medical technologies, oral care solutions, health information technology, and purification and filtration systems.
VETRUN LLC is intentionally structured as a lean, project-focused organization designed to deliver complex, regulated medical products with speed, accountability, and cost efficiency. Rather than maintaining large internal departments for legal, regulatory, testing, manufacturing, and specialized engineering functions, VETRUN utilizes a distributed execution model, contracting with best-in-class service providers as required by each program. VETRUN works exclusively on one project at a time, enabling full leadership focus, rapid decision-making, and disciplined execution without competing internal priorities. This model allows VETRUN to assemble a tailored team of subject matter experts for each program, including legal counsel, FDA regulatory consultants, accredited testing laboratories, industry experts, contract manufacturers, and design and development partners. These relationships are not ad hoc. VETRUN has curated a robust network of U.S.-based (“Made in USA”) companies over more than 20 years, selecting partners with demonstrated experience in FDA-regulated medical devices, government programs, and high-reliability manufacturing. This long-standing network enables VETRUN to rapidly mobilize proven resources, scale capabilities as needed, and replace or augment services without disruption. By avoiding fixed overhead associated with large permanent staff and facilities, VETRUN maintains low indirect costs while preserving access to deep technical and regulatory expertise. This structure enhances flexibility, reduces financial risk, and allows resources to be applied directly to execution and milestone achievement rather than administrative burden. This execution model results in a company that is fast-moving, adaptable, and highly responsive, well-suited for time-sensitive programs requiring regulatory rigor, domestic manufacturing, and close coordination with Government stakeholders. VETRUN’s role is to serve as the integrator and accountable authority, ensuring that all partners operate cohesively toward a common objective while maintaining schedule discipline, quality compliance, and mission focus.
The University of Maryland, Baltimore (UMB) is Maryland’s public health, law, and human services university. It is dedicated to improving the human condition and serving the public good through education, research, clinical care, and service. UMB is the founding campus of the University System of Maryland and offers a wide range of professional degrees in health care, human services, and law.
4TEEN4 Pharmaceuticals GmbH is a German biotech company pioneering precision medicine in critical care, with a mission to develop causal therapies for acute cardiovascular complications, particularly shock. The company focuses on targeting cDPP3, a key mediator in circulatory failure, and is advancing Procizumab, a first-in-class antibody, through clinical development. With a leadership team boasting over 150 years of pharma experience and a strong network of international researchers, 4TEEN4 aims to address unmet medical needs and improve patient outcomes where current therapies are inadequate.
The University of North Carolina Wilmington (UNCW) is a top doctoral and research institution located in Wilmington, North Carolina. Established in 1947, UNCW has grown to serve nearly 18,000 students and employs about 2,500 staff. The university is dedicated to providing a powerful academic experience that fosters creative inquiry, critical thinking, and thoughtful expression in a beautiful coastal setting. UNCW is committed to educational excellence, community engagement, and global connections, making it a vibrant part of the southeastern North Carolina community. UNCW also emphasizes the importance of freedom of expression and mutual respect within its diverse community.
The University of Missouri-Kansas City (UMKC) is dedicated to transforming today's learners into tomorrow's leaders through innovative education, research, and community engagement. With over 125 academic programs, UMKC fosters a diverse and inclusive environment that empowers students to achieve their goals and make a positive impact in their communities.
Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world, dedicated to providing high-quality, patient-centered care. With a history of innovation spanning nearly 150 years, Mayo Clinic is committed to transforming healthcare through research, education, and compassionate care, ensuring that the best possible treatment is available to everyone.
Since its founding in 1878, Shionogi has been dedicated to developing innovative treatments to improve the lives of patients worldwide. The company focuses on addressing global health challenges, including antimicrobial resistance and COVID-19, through a commitment to scientific excellence and strategic partnerships.
RxMP Therapeutics is dedicated to developing innovative therapies aimed at preventing and treating hemorrhage and excessive bleeding associated with trauma, surgery, or bleeding disorders. The company focuses on creating novel hemostatic agents that can effectively stop bleeding while minimizing the risk of unwanted clotting elsewhere in the body. Their lead product, RMP-402, has significant market potential and is backed by substantial funding to support its development.
Adipothera develops therapies targeting the stromal microenvironment to treat diseases driven by fibrosis and inflammation. Using AI, computation, and multi-modal datasets, the company generates and validates drug candidates aimed at repairing tissue rather than managing symptoms. Their approach focuses on stromal reprogramming for conditions such as radiation injury, lymphedema, and pathological bone formation.
Temple University is Philadelphia’s only public university and a global center of academic excellence. It is classified as an R1 institution, indicating very high research activity, and offers over 600 academic programs across 17 diverse schools and colleges. The university is committed to providing accessible education that fosters positive change and prepares students to become leaders in their fields. Additionally, Temple emphasizes a vibrant campus life enriched by arts, culture, and a commitment to diversity and inclusivity. The university also promotes a tobacco-free environment to enhance the health and well-being of its community. Temple's athletics program further enhances student life, with 19 varsity teams competing at the NCAA Division I level, fostering school spirit and community engagement.
The Office of Sponsored Projects Administration (OSPA) at the University of Kentucky is dedicated to transforming tomorrow by streamlining grants and contracts. OSPA provides essential services to faculty and staff, including assistance with proposal preparation, award negotiation, and compliance with sponsor policies.
Southwest Research Institute (SwRI) is a nonprofit research and development organization that provides independent, premier services to government and industry clients. Founded in 1947, SwRI is committed to advancing science and technology to benefit humanity, focusing on innovative solutions that improve human health and safety. With a diverse range of technical divisions, SwRI addresses complex challenges in various fields including mechanical engineering, materials, aerospace, automotive, biomedical, and more.
Celestial Therapeutics is a Johnson & Johnson Innovations-JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.
Persist AI is a biotechnology company pioneering the use of AI-driven robotics to accelerate and transform pharmaceutical formulation development. Their mission is to deliver life-saving drugs faster, with fewer side effects, and improved patient outcomes by leveraging advanced automation, machine learning, and high-throughput experimentation. Persist AI's integrated platform addresses the bottlenecks of traditional drug formulation by combining custom robotics, computational chemistry, and proprietary AI models, enabling rapid, scalable, and cost-effective development of complex drug delivery systems such as long-acting injectables. With a global presence and a team of experts in drug delivery, automation, and machine learning, Persist AI is committed to making advanced drug delivery systems more accessible and efficient for the pharmaceutical industry worldwide. The company also demonstrates a strong commitment to data protection, privacy, and security, implementing robust technical and organizational measures in compliance with international standards.
The University of Arizona Applied Research Corporation (UA-ARC) is a non-profit organization affiliated with the University of Arizona, dedicated to leveraging the university's strengths in research and education to address national security challenges. UA-ARC aims to deliver innovative solutions and foster collaborations between academia, industry, and government.
Lumen Bioscience is dedicated to unlocking the full potential of biologic drugs by transforming their development, cost, and accessibility. Utilizing patented technology, Lumen aims to develop biologic drugs faster, safer, and more effectively than traditional methods, addressing diseases that have been neglected by conventional drug-making tools.
The University of Utah (UU) is a leading research institution recognized for its research activity and commitment to innovation and discovery. As an R1 Institution, it is dedicated to advancing knowledge and solving critical problems that challenge our national security interests and impact the global community. We foster interdisciplinary collaboration and provide resources to drive transformative research focused on enhancing medical care superiority for the U.S. Department of Defense (DoD) through advanced medical and engineering research sponsored by our Applied Medical & Engineering Laboratory (AM&E Lab). As a leading public university, UU also provides healthcare services to seven states in the Intermountain West, with the largest catchment of remote and austere frontier territory for any academic center. Leveraging its geographic advantage, technological and commercialization strengths, expertise in medical services, and leading-edge, core engineering competencies, UU is uniquely positioned to address the nation's critical national security interests.
The Institute for Biohealth Innovation (IBI) at George Mason University unites over 300 faculty and thousands of students across 34 departments to advance human health and well-being through innovative research. The IBI focuses on major health challenges, including infectious diseases, cancer, brain and behavior, and cardiovascular health, collaborating with national and international partners to implement solutions that enhance health outcomes.
The University of Minnesota's Research and Innovation Office (RIO) serves as a central resource for conducting, managing, and sponsoring research. It aims to facilitate collaborative research that addresses complex problems and promotes innovations that improve lives. RIO oversees research compliance and administration, fostering a culture of integrity and ethical practices in research. Additionally, RIO is committed to enhancing research capacity through various funding opportunities and strategic initiatives, including the management of specialized facilities for biocontainment research.
The University of Notre Dame, founded in 1842, is a prestigious Catholic research university located in South Bend, Indiana. It is dedicated to providing a holistic education that integrates faith, reason, and service to others. The university aims to be a leading global Catholic research institution, fostering a community of scholars committed to inquiry, justice, and the common good.
New York University (NYU) is a global university that connects talented and ambitious individuals in some of the world's greatest cities. Its mission is to be a top-quality institution, providing a diverse range of academic programs and opportunities for students to engage with the world's challenges. NYU is committed to fostering innovation and entrepreneurship, and it emphasizes diversity, equity, and inclusion in its educational mission. Founded in 1831, NYU has evolved to become a leader in higher education, with a commitment to accessibility and a diverse student body. NYU offers a wide array of academic programs, including accelerated studies and online education, catering to the needs of a global student population.
ReliOx Corporation is a U.S.-based advanced materials and medical technology company with a clean oxidation platform for on-demand generation of pH-neutral aqueous chlorine dioxide. The ReliOx platform enables safe, controlled oxidation at the point of use without acids, electricity, or hazardous intermediates—addressing long-standing limitations that have historically prevented chlorine dioxide from being used routinely in medical and operational environments. ReliOx directly supports the important core objectives aligned with MTEC members: improving trauma care, reducing infection risk, enabling care in austere and resource-constrained settings, and accelerating transition of dual-use technologies from non-regulated markets into regulated medical and defense applications. The platform’s defining feature is not a new chemical agent, but a novel generation method that produces true chlorine dioxide only at the moment of use, in a neutral pH aqueous form compatible with tissue, metals, polymers, elastomers, and sensitive electronics. ReliOx is advancing an initial wound cleansing and irrigation use case that aligns closely with military and emergency medicine needs, including contaminated wounds, blast injuries, and prolonged field care. The system’s on-demand architecture eliminates the need to store reactive disinfectants, reduces logistical burden, and supports distributed medical operations, a priority across DoD, BARDA, and ONR programs. This makes the platform particularly relevant for battlefield medicine, forward surgical teams, and humanitarian or disaster response scenarios. In parallel, ReliOx operates VetiOx, a veterinary-focused pathway that applies the same platform to animal wound care (including equine). This strategy generates early operational data and clinician familiarity while remaining aligned with long-term human medical translation—an approach consistent with MTEC’s emphasis on de-risking technologies prior to advanced development. The ReliOx platform is inherently dual-use. All commercial, veterinary, food safety, and medical applications share the same resin-based generation mechanism, enabling efficient manufacturing, rapid scaling, and consistent safety characteristics across use cases. This platform approach allows ReliOx to support incremental transition from non-regulated and veterinary markets into FDA-regulated medical devices and DoD-relevant medical countermeasures without fundamental redesign. ReliOx represents a strong MTEC-aligned opportunity at the intersection of advanced chemistry, trauma care, infectious disease mitigation, and distributed manufacturing. The company offers a defensible intellectual property position, a clear regulatory strategy, and a near-term path to operational relevance for military medicine and biodefense stakeholders .
Remedor Biomed is a clinical research stage biopharmaceutical company focused on revolutionizing complex wound treatment through patented technology. The company aims to provide innovative solutions for diabetic foot ulcers and complex skin wound conditions, significantly impacting patients' lives and healthcare systems.
Vasomune Therapeutics is a private clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases associated with vascular dysfunction. Their lead drug candidate, Pegevongitide (AV-001), enhances the body's ability to reverse vascular endothelial instability and vascular leak, particularly in conditions such as Acute Respiratory Distress Syndrome (ARDS), hemorrhage, and following toxin exposure.
Northwestern University is a prestigious institution dedicated to fostering a diverse and inclusive environment, promoting academic excellence, and engaging in impactful research. With campuses in Evanston, Chicago, and Doha, Qatar, Northwestern emphasizes global engagement and community involvement, preparing students to tackle complex challenges through interdisciplinary collaboration and innovative thinking.
The University of Iowa is dedicated to providing a comprehensive educational experience that fosters academic excellence, research opportunities, and a vibrant student life. With a commitment to accessibility and inclusivity, the university aims to prepare its students for success in various fields while promoting a supportive community.
Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.
The University of Alaska Fairbanks (UAF) is a Land, Sea, and Space Grant university and an international center for research, education, and the arts, emphasizing the circumpolar North and its diverse peoples. UAF integrates teaching, research, and public service as it educates students for active citizenship and prepares them for lifelong learning and careers.
New Jersey Institute of Technology (NJIT) is a leading public research university dedicated to providing students with a world-class education in STEM fields and beyond. With a commitment to academic excellence, NJIT prepares students to be leaders in the most in-demand fields through innovative programs, expert faculty, and extensive research opportunities. NJIT is recognized for its affordability and return on investment, making it a top choice for students seeking a quality education. NJIT is also ranked among the top public universities in the nation, known for its diverse student body and commitment to fostering an inclusive environment.
Inhalon Biopharma is a clinical-stage biotechnology company focused on developing innovative inhaled antibody treatments for acute respiratory infections. Their mission is to provide effective and convenient treatment options for conditions such as RSV, hMPV, influenza, and SARS-CoV-2, utilizing a unique 'test-to-treat' model that enhances patient care.
ClearCure Biosciences is a clinical-stage biopharmaceutical company focused on developing non-toxic, first-in-class and best-in-class therapies for cancer, infectious diseases, sepsis, neurological diseases, and cardiovascular conditions. The company emphasizes drugging challenging targets, leveraging proprietary small molecules, nanotechnology, new oncology cell therapies, new transdermal drug delivery technology, AI and omics-driven approaches, and digital health solutions to address serious unmet medical needs. The company is currently seeking collaborators and partnerships.
The University of Arkansas for Medical Sciences Office of Research and Sponsored Programs (ORSP) is dedicated to supporting UAMS faculty in acquiring, performing, and administering projects funded by external sources. The ORSP ensures compliance with policies, negotiates award terms, liaises between investigators and sponsors, and manages subcontracts.
Founded by Thomas Jefferson in 1819, the University of Virginia is a prestigious public university that emphasizes the advancement of human knowledge, education of leaders, and cultivation of an informed citizenry. It is recognized for its commitment to academic excellence, vibrant student life, and a strong alumni network, making it one of the top public universities in the United States.
The University of Missouri is dedicated to advancing research, innovation, and impact through a comprehensive support system for faculty, students, and staff. It aims to foster collaboration, enhance economic development, and promote entrepreneurship, while ensuring compliance with research regulations and ethical standards. The university also emphasizes the importance of interdisciplinary partnerships and provides resources to support veteran entrepreneurs through programs like the Entrepreneurship Bootcamp for Veterans.
The University of Massachusetts Lowell (UML) is dedicated to providing a comprehensive educational experience that prepares students for success in their careers and lives. With over 200 degree programs and a commitment to research and community engagement, UML fosters a vibrant learning environment for its diverse student body.
Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.
The University of Nebraska Medical Center (UNMC) is dedicated to transforming lives through premier educational programs, innovative research, and extraordinary patient care. Founded in 1869, UNMC is a leader in health sciences education and research, serving as a vital resource for Nebraska and beyond.
The University of Georgia (UGA) is dedicated to facilitating instruction, scholarly and creative activity, and research collaborations across disciplines. UGA is a leader in research-based products and innovation, significantly impacting the state of Georgia and beyond through its extensive research initiatives and academic programs.
MassBiologics, part of UMass Chan Medical School, is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States. With over 100 years of experience, it is dedicated to improving public health through the research, development, and production of biologic products, including vaccines and monoclonal antibodies.
The Medical University of South Carolina (MUSC) is South Carolina’s premier biomedical research institution, dedicated to advancing health through innovative research, education, and clinical care. With over $300 million in research funding and a commitment to addressing pressing health challenges, MUSC fosters collaboration among faculty, staff, and community partners to translate scientific discoveries into impactful health solutions. The South Carolina Clinical & Translational Research Institute (SCTR) at MUSC supports innovative research across the translational spectrum, from basic science to population health, including patient-centered and community-engaged research.
The UCI Office of Research is dedicated to supporting and enhancing the creative and scholarly activities of UCI faculty and researchers. It provides central administrative support for research programs, ensuring compliance with regulations and fostering an environment conducive to research and innovation.
Gel4Med is a commercial-stage company pioneering the use of smart, bioinspired materials to address major challenges in medicine. Founded out of Harvard Innovation Labs, Gel4Med leverages its proprietary Smart Materials Platform™ (SMP™) to develop advanced therapeutics and devices, with a mission to enhance health outcomes and access for all patients. The company is committed to creating novel biomaterials that improve regenerative medicine and surgical solutions, and has achieved significant milestones including FDA clearance for its lead wound care product, G4Derm™ Plus.
The Clemson University Research Foundation (CURF) is dedicated to advancing the research enterprise at Clemson University by connecting faculty and students with industry partners. CURF facilitates the commercialization of university technologies, supports research collaboration, and promotes innovation through various funding and support programs.
Hemerus Medical, LLC specializes in designing and developing innovative blood collection, processing, preservation, and storage technologies. Our mission is to improve patient transfusion outcomes and ensure the availability of high-quality, life-saving blood products. Hemerus aims to extend the shelf life of blood products and enhance transfusion safety through advanced technologies like leukocyte reduction filters and novel anticoagulant and additive solutions.
Virginia Tech is a leading research institution dedicated to improving the quality of life and the human condition through education, research, and community engagement. With a commitment to its motto, 'Ut Prosim' (That I May Serve), Virginia Tech fosters a collaborative environment that integrates technology into all disciplines, preparing scholars to be leaders and problem-solvers.
Radiatric Inc. is dedicated to developing and commercializing innovative technologies to improve outcomes for patients with blood stream infections that can lead to sepsis, and septic shock. Antimicrobial resistance is a serious global health threat. Our flagship medical device, our RAD-01 system, is an extracorporeal non-antibiotic device designed to treat blood stream infections by targeting and killing pathogens even multi drug-resistant organisms. The company's focus is on non-pharmacological methods of killing pathogens, aiming to reduce the mortality and long-term effects associated with sepsis.
LSU Health Sciences Center New Orleans is dedicated to educating future health professionals and scientists, advancing research, and providing exceptional healthcare. With six professional schools and numerous affiliated hospitals, LSUHSC-NO aims to improve health outcomes and address health equity challenges in Louisiana.
Relevium Medical is a pharmaceutical company based in Ireland and the US, founded in 2019 as a spin-out from the University of Galway’s BioInnovate Programme, the only European affiliate of Stanford BioDesign. With support from Y Combinator, Enterprise Ireland and the European Innovation Council, the company is developing novel hydrogel-based therapeutics for chronic disorders, leveraging natural biopolymers and active agents for targeted, long-lasting treatment. Relevium has a world-class clinical advisory board and a growing pipeline including products for osteoarthritis, painful bladder, neurogenic bladder, & trauma wound infections. To date the company has secured a total of $8 million non-dilutive funding and private seed investment.
Biophoundry specializes in advancing scalable engineered phage-based solutions for therapeutics, diagnostics, and bio-molecular engineering. It is shifting the paradigm from phage discovery to phage design. Its team leverages expertise in synthetic biology, machine learning, and data science to accelerate the development of precision antibiotics and address critical healthcare challenges such as antimicrobial resistance.
Northeastern University is a global research university founded in 1898, renowned for its experiential learning model, high-impact research, and deep partnerships. The university emphasizes innovative teaching and research that engage students, faculty, and alumni in solving real-world problems, fostering a dynamic and inclusive community across its 13 campuses worldwide.
The University of Montana (UM) is a flagship public research university located in Missoula, Montana. Established in 1893, UM offers a wide range of undergraduate and graduate programs, emphasizing research, creativity, and community engagement. With a commitment to academic excellence and public service, UM aims to transform lives through education and research, fostering a diverse and inclusive environment for its students.
CMTx Biotech, Inc. is an emerging biopharmaceutical company working to develop and commercialize host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Our lead drug candidate is a clinically-tested, highly-stable, orally-administered small molecule that has been shown to improve survival and prevent lung injury in a wide variety of animal models of sepsis, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) across several species, including mice, rats, hamsters, pigs and sheep. Having already secured approximately $4M in funding to-date, including $3.6M in NIH SBIR/STTR grants, we are actively seeking non-dilutive funding, private investment capital and/or an established strategic partner to help advance human clinical trials and FDA Animal Rule development, as well as to expand our product pipeline.
The University at Buffalo is a leading public research university and flagship of the SUNY System, recognized for its innovative research and commitment to societal impact. It aims to transform scientific and technological breakthroughs into global impact, addressing complex challenges through interdisciplinary collaboration.
UC San Francisco is a leading university dedicated to advancing health worldwide through preeminent biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. With a commitment to public service, UCSF aims to innovate health care approaches for vulnerable populations and train the next generation of health professionals.
Brinter is a pioneering US-based MedTech firm focused on revolutionizing tissue engineering through the development of 3D bioprinted biocomposite regenerative implants, known as BioMods™, which aim to restore damaged tissue and replace conventional implants, launching in orthopedics/tendons and ligaments. The company driven by a team of visionary entrepreneurs and leading bioscientists and engineers.
Calla Lily Clinical Care develops patented medical device technologies engineered to improve intravaginal drug delivery for women's health, focusing on clinical needs such as fertility support, pregnancy management, prevention of recurrent miscarriage, and restoration of the vaginal microbiome. Recognized for innovation, the company maintains collaborative partnerships with clinical and academic institutions and secures funding to advance clinical trials and R&D. Their technology is designed for leak prevention, convenience, and dosing confidence, with a strong commitment to sustainability and social impact as a certified B-Corporation.
NeuEsse Inc. is dedicated to advancing skin health through innovative plant-based technologies. Their mission is to provide effective solutions for skin repair, addressing challenges such as severe burns, wounds, and trauma. Their flagship product, OmegaSkin™, is a human skin substitute made from soy protein, designed to enhance healing outcomes with minimal scarring. NeuEsse aims to meet the unmet needs in wound treatment, offering products that are sustainable, vegan-friendly, and require no special handling.
VitaKey is pioneering a new era in nutrition by applying precision delivery technology to enhance the nutrient density of foods and beverages. Developed at MIT, Langer Lab, and co-founded by Dr. Robert S. Langer, VitaKey's platforms aim to address global health challenges, including diet related diseases such as obesity, heart disease and diabetes. VitaKey technologies ensure the stability and controlled release of nutrients (macronutrients, micronutrients, probiotics, bioactives, etc.) to improve bioavailability and enhance the functionality of foods and beverages. VitaKey creates all natural food and beverage solutions to enhance human performance, boost satiety, and improve the health and wellness of all consumers.
SUNY Upstate Medical University is a leading academic medical center in Central New York, dedicated to providing exceptional patient care, advancing medical research, and educating future healthcare professionals. As the region's only Level I trauma center and a Magnet recognized institution, Upstate is committed to delivering cutting-edge, life-saving treatments and fostering a compassionate, patient-centered environment. The university also plays a significant role in the community through outreach programs and is recognized as one of America's best large employers by Forbes.
Hemanext is a privately held medical technology company specializing in oxygen-controlled red blood cell processing and storage systems for transfusion medicine. The company develops, manufactures, and commercializes innovative storage solutions that preserve the quality and function of red blood cells by limiting oxygen and carbon dioxide exposure, with the goal of improving transfusion outcomes for patients with chronic and acute conditions. Hemanext's products have received FDA De Novo marketing authorization and CE Mark certification, enabling global distribution. The company is recognized for its focus on scientific evidence, operational compatibility, and strategic partnerships with blood establishments and clinical researchers.
Washington State University (WSU) is a public research university dedicated to improving lives by serving the public good. With a commitment to unlocking possibilities, WSU empowers students, faculty, and others to create a world where all people can thrive. The university offers a diverse range of academic programs across its six campuses and is recognized for its high research activity and community engagement.
Northstar owns IP around the use of antibody fragments and nucleic acids to rapidly diagnose and treat bacterial and viral infections. With numerous applications to sepsis and bioterrorism countermeasure, Northstar seeks partnerships with other forward thinking companies and government entities to protect our military and enhance homeland security.
Altrazeal Life Sciences Inc. is a specialty medical technology company dedicated to developing and commercializing innovative drug delivery systems. Their mission is to improve patient outcomes by providing comprehensive solutions for patients, providers, and payers. The company is known for its patented Altrazeal® Transforming Powder Dressing, which optimizes the wound healing environment and supports tissue repair.
UCLA is a leading public research university located in Los Angeles, California. It is renowned for its commitment to the creation, dissemination, preservation, and application of knowledge for the advancement of global society. With a rich history of academic and athletic excellence, UCLA offers a comprehensive environment that supports both academic and personal growth. The university is dedicated to fostering innovation and making a significant impact on the world through groundbreaking research and transformative practices.
Triple Ring accelerates the pace of innovation allowing our partner companies to drive growth, start new businesses, launch breakthrough products, improve health, and change lives. We are a healthcare-focused Corporate Growth Lab headquartered in Silicon Valley, with offices in Boston, Toronto, and Copenhagen. Our services span three key business lines: Technology translation for US government programs, Corporate Growth Labs, and Technology and product development services. Founded in 2005, Triple Ring has an unparalleled track record supporting clients from startups to many of the world’s largest MedTech and Life Sciences companies.
Rx Bandz is dedicated to developing innovative, next-generation auto-injectors and life-saving formulations that provide simple solutions for patients, first responders, and the military. Their mission is to enhance the delivery of injectable medications, ensuring accessibility and ease of use for anyone, anytime, anywhere.
Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.
The Medical College of Wisconsin (MCW) is dedicated to transforming healthcare through innovative education, research, and patient care. With a focus on academic medicine, MCW aims to improve the health of communities by fostering a collaborative learning environment that integrates medical education with groundbreaking research and comprehensive patient care.
SIMMEC Training Solutions is a woman-owned, service-disabled veteran-owned small business (WOSB/SDVOSB) providing high-fidelity Tactical Combat Casualty Care (TCCC) training using advanced live models. We specialize in delivering immersive, operationally relevant training environments that replicate battlefield trauma conditions under stress, time pressure, and environmental chaos. Our cadre includes former Special Operations medics and trauma clinicians with real-world deployment experience. All courses align with DoD and CoTCCC standards, supporting combat medics, deploying providers, and allied partner forces. Our training incorporates high-fidelity manikins and cadavers where appropriate, but centers on biologically responsive live tissue models to deliver the highest level of realism and decision-making complexity. SIMMEC is committed to ensuring that live tissue training remains the foundational standard for validating emerging trauma technologies and enhancing military medical readiness. As a Non-Traditional Defense Contractor, SIMMEC is uniquely positioned to support MTEC-funded research through: access to validated, biologically responsive training platforms; benchmark data for simulation and wearable validation; performance observation to support AI and Autonomous Casualty Care (AC2) development; and collaboration in hybrid training model innovation (sim-to-live). We are actively seeking partners involved in trauma simulation, AI/ML triage systems, wearable tech, and data-integrated battlefield medical solutions.
Indiana University is dedicated to building a better future through education, research, and community engagement. With a commitment to academic excellence, IU offers a diverse range of programs across its nine campuses, fostering an inclusive environment for over 90,000 students from around the world. IU is also at the forefront of groundbreaking research, particularly in areas such as brain health and Alzheimer's disease.
KaloCyte, Inc. is a pre-clinical stage biotech company focused on developing ErythroMer™, a dried, bio-inspired artificial red blood cell that is shelf-stable without refrigeration. This innovative solution aims to address the critical need for blood substitutes in emergency situations where stored red blood cells are unavailable, undesirable, or in short supply. Founded by a team of experts in physiology, bioengineering, and trauma care, KaloCyte is supported by significant federal grants and investor funding, positioning it to advance to first-in-human trials.
MyFitStrip is dedicated to enhancing oral and metabolic health through clinically-supported products that utilize the therapeutic potential of prebiotic formulations to boost nitric oxide levels. Delivered via topical oral lozenges and chewing gums, these products rapidly increase local nitric oxide concentrations to support a healthy oral microbiome and suppress pathogenic organisms in the oral and nasal cavities, which are key entry points and reservoirs for many infections, including COVID-19. By focusing on oral microbiome optimization, MyFitStrip promotes nitric oxide bioavailability, a molecule vital for vascular function, immune defense, and systemic wellness. The company's product line includes prebiotic chewing gums, slow-release lozenges, and personalized saliva test strips, all designed to support cardiovascular health, physical performance, respiratory resilience, and overall oral health.
Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.
The University of Tennessee, Knoxville is dedicated to advancing knowledge and understanding through research, scholarship, and creative work. The Office of Research, Innovation, and Economic Development supports faculty, staff, and students in developing competitive proposals and fostering a strong culture of research integrity, aiming to create a more just, prosperous, and sustainable world.
Tensentric is a contract design and manufacturing firm focused solely on medical device, in vitro diagnostic, and advanced therapy markets. We're ISO13485 certified and FDA registered to help our clients bring their new technology and products to market.
Founded in 2015, Omnix Medical is a clinical-stage biopharmaceutical company dedicated to developing novel antibiotic agents to combat infections caused by drug-resistant bacteria. Their innovative technology focuses on natural antimicrobial peptides, engineered for therapeutic use, targeting severe hospital-acquired infections and addressing the urgent threat posed by multidrug-resistant pathogens. The company is building a pipeline of first-in-class anti-infectives designed to treat severe, potentially lethal infections associated with multi-drug resistances.
Zymeron is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative healthcare technologies that deliver step-change performance. The company focuses on proactive health solutions to address critical unmet needs in the pharmaceutical sciences, particularly in drug delivery and formulation technologies.
The Center for Military Medicine Research (CMMR) at the University of Pittsburgh is dedicated to advancing medical research for wounded service members and their families. The center focuses on trauma, emergency, and critical care, leveraging the university's strengths in medical and engineering fields, and collaborating with Carnegie Mellon University's robotics and AI expertise. CMMR aims to enhance trauma care for warfighters and civilians, contributing to the defense innovation economy.
The Texas A&M Engineering Experiment Station (TEES) is a state agency and part of the Texas A&M University System, dedicated to improving lives through engineering research, workforce development, and technology transition. TEES collaborates with industry, academia, and government to provide innovative solutions to global technical challenges.

Arizona State University
ASU Crosscutting Technologies to Enhance Military Medical Readiness and Resilience
Dr. Rachel Cassalia leads MTEC-supported efforts at ASU to shift military health from reactive care to proactive readiness through data-driven prevention.
University of Pittsburgh
Topical Metformin Lotion for Tendinopathy Prevention
University of Pittsburgh study shows topical metformin prevents overuse tendon injury. This work was sponsored through MTEC project 22-02-MPAI-014.
Theradaptive
Theradaptive’s RESTORE Trial Initiation for OsteoAdapt™ DE
Theradaptive launches RESTORE Phase I/II trial of OsteoAdapt™ DE for faster, precision bone healing in craniofacial injuries. MTEC-funded study targets improved recovery for military and civilian patients.
Altec
Autonomous Rehabilitation Device for Improved Recovery in Warfighters
The OSCIR platform—developed by Altec Inc in collaboration with the Naval Health Research Center—is bringing clinical-grade, real-time movement analysis to the front lines. Funded under MTEC-22-02-MPAI